257 related articles for article (PubMed ID: 26238627)
21. Immunohistochemical and molecular genetic study on epithelioid glioblastoma: Series of seven cases with review of literature.
Khanna G; Pathak P; Suri V; Sharma MC; Chaturvedi S; Ahuja A; Bhardwaj M; Garg A; Sarkar C; Sharma R
Pathol Res Pract; 2018 May; 214(5):679-685. PubMed ID: 29615337
[TBL] [Abstract][Full Text] [Related]
22. Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.
Yamada S; Kipp BR; Voss JS; Giannini C; Raghunathan A
Am J Surg Pathol; 2016 Feb; 40(2):279-84. PubMed ID: 26414224
[TBL] [Abstract][Full Text] [Related]
23. Analysis of Histomorphologic/Molecular Association and Immune Checkpoint Regulators in Epithelioid Glioblastoma and Pleomorphic Xanthoastrocytoma: Are These Tumors Potential Candidates for Immune Checkpoint Blockade?
Mahajan S; Singh J; Dandapath I; Jha P; Chaturvedi S; Ahuja A; Bhardwaj M; Saran R; Garg A; Sharma MC; Manjunath N; Suri A; Sarkar C; Suri V
Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):84-95. PubMed ID: 38158760
[TBL] [Abstract][Full Text] [Related]
24. Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma.
Tonse R; Gupta T; Epari S; Shastri JG; Gurav M; Bano N; Jalali R
J Neurooncol; 2018 Jan; 136(2):343-350. PubMed ID: 29147864
[TBL] [Abstract][Full Text] [Related]
25. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.
Dias-Santagata D; Lam Q; Vernovsky K; Vena N; Lennerz JK; Borger DR; Batchelor TT; Ligon KL; Iafrate AJ; Ligon AH; Louis DN; Santagata S
PLoS One; 2011 Mar; 6(3):e17948. PubMed ID: 21479234
[TBL] [Abstract][Full Text] [Related]
26. PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma.
Rodriguez EF; Scheithauer BW; Giannini C; Rynearson A; Cen L; Hoesley B; Gilmer-Flynn H; Sarkaria JN; Jenkins S; Long J; Rodriguez FJ
Acta Neuropathol; 2011 Mar; 121(3):407-20. PubMed ID: 21113787
[TBL] [Abstract][Full Text] [Related]
27. Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression.
Chappé C; Padovani L; Scavarda D; Forest F; Nanni-Metellus I; Loundou A; Mercurio S; Fina F; Lena G; Colin C; Figarella-Branger D
Brain Pathol; 2013 Sep; 23(5):574-83. PubMed ID: 23442159
[TBL] [Abstract][Full Text] [Related]
28. The evolution of pleomorphic xanthoastrocytoma: from genesis to molecular alterations and mimics.
Mahajan S; Dandapath I; Garg A; Sharma MC; Suri V; Sarkar C
Lab Invest; 2022 Jul; 102(7):670-681. PubMed ID: 35031693
[TBL] [Abstract][Full Text] [Related]
29. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.
Nakajima N; Nobusawa S; Nakata S; Nakada M; Yamazaki T; Matsumura N; Harada K; Matsuda H; Funata N; Nagai S; Nakamura H; Sasaki A; Akimoto J; Hirato J; Yokoo H
Brain Pathol; 2018 Sep; 28(5):663-673. PubMed ID: 29105198
[TBL] [Abstract][Full Text] [Related]
30. A case of an epithelioid glioblastoma with the BRAF V600E mutation colocalized with BRAF intact low-grade diffuse astrocytoma.
Kuroda J; Nobusawa S; Nakamura H; Yokoo H; Ueda R; Makino K; Yano S; Kuratsu J
Neuropathology; 2016 Apr; 36(2):181-6. PubMed ID: 26375727
[TBL] [Abstract][Full Text] [Related]
31. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK
Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727
[TBL] [Abstract][Full Text] [Related]
32. Composite pleomorphic xanthoastrocytoma-epithelioid glioneuronal tumor with BRAF V600E mutation - report of three cases.
Aisner DL; Newell KL; Pollack AG; Kleinschmidt-Demasters BK; Steinberg GK; Smyth LT; Vogel H
Clin Neuropathol; 2014; 33(2):112-21. PubMed ID: 24321241
[TBL] [Abstract][Full Text] [Related]
33. Anaplastic PXA in adults: case series with clinicopathologic and molecular features.
Schmidt Y; Kleinschmidt-DeMasters BK; Aisner DL; Lillehei KO; Damek D
J Neurooncol; 2013 Jan; 111(1):59-69. PubMed ID: 23096133
[TBL] [Abstract][Full Text] [Related]
34. Molecular Features and Prognostic Factors of Pleomorphic Xanthoastrocytoma: A Collaborative Investigation of the Tohoku Brain Tumor Study Group.
Ono T; Sasajima T; Shimizu H; Natsumeda M; Kanamori M; Asano K; Beppu T; Matsuda K; Ichikawa M; Fujii Y; Ohkuma H; Ogasawara K; Sonoda Y; Saito K; Nobusawa S; Nakazato Y; Kitanaka C; Kayama T; Tominaga T;
Neurol Med Chir (Tokyo); 2020 Nov; 60(11):543-552. PubMed ID: 33071274
[TBL] [Abstract][Full Text] [Related]
35. Clinical, Morphological, and Molecular Study on Grade 2 and 3 Pleomorphic Xanthoastrocytoma.
Zhang H; Ma XJ; Xiang XP; Wang QY; Tang JL; Yu XY; Xu JH
Curr Oncol; 2023 Feb; 30(2):2405-2416. PubMed ID: 36826144
[TBL] [Abstract][Full Text] [Related]
36. Morphological and molecular features of astroblastoma, including BRAFV600E mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults.
Lehman NL; Hattab EM; Mobley BC; Usubalieva A; Schniederjan MJ; McLendon RE; Paulus W; Rushing EJ; Georgescu MM; Couce M; Dulai MS; Cohen ML; Pierson CR; Raisanen JM; Martin SE; Lehman TD; Lipp ES; Bonnin JM; Al-Abbadi MA; Kenworthy K; Zhao K; Mohamed N; Zhang G; Zhao W
Neuro Oncol; 2017 Jan; 19(1):31-42. PubMed ID: 27416954
[TBL] [Abstract][Full Text] [Related]
37. Clinical relevance of BRAF status in glial and glioneuronal tumors: A systematic review.
Sugiura Y; Nagaishi M
J Clin Neurosci; 2019 Aug; 66():196-201. PubMed ID: 31147232
[TBL] [Abstract][Full Text] [Related]
38. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.
Ho CY; Mobley BC; Gordish-Dressman H; VandenBussche CJ; Mason GE; Bornhorst M; Esbenshade AJ; Tehrani M; Orr BA; LaFrance DR; Devaney JM; Meltzer BW; Hofherr SE; Burger PC; Packer RJ; Rodriguez FJ
Acta Neuropathol; 2015 Oct; 130(4):575-85. PubMed ID: 26264609
[TBL] [Abstract][Full Text] [Related]
39. Expression of the CD34 antigen in pleomorphic xanthoastrocytomas.
Reifenberger G; Kaulich K; Wiestler OD; Blümcke I
Acta Neuropathol; 2003 Apr; 105(4):358-64. PubMed ID: 12624789
[TBL] [Abstract][Full Text] [Related]
40. MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma.
Lohkamp LN; Schinz M; Gehlhaar C; Guse K; Thomale UW; Vajkoczy P; Heppner FL; Koch A
PLoS One; 2016; 11(6):e0156422. PubMed ID: 27253461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]